Brief: Santhera And Reveragen Announce Positive Topline Results With Vamorolone In Vision-DMD Study

Santhera Pharmaceuticals Holding AG

01/06/2021 06:07

June 1 (Reuters) - SANTHERA PHARMACEUTICALS HOLDING AG
 SANN.S :
    * SANTHERA AND REVERAGEN ANNOUNCE POSITIVE AND STATISTICALLY
HIGHLY SIGNIFICANT TOPLINE RESULTS WITH VAMOROLONE IN PIVOTAL
VISION-DMD STUDY
    * SANTHERA PLANS TO FILE A NEW DRUG APPLICATION (NDA) WITH
US FDA
IN Q1-2022, REQUESTING PRIORITY REVIEW

Source text for Eikon:  ID:nGNE91t1Fr 
Further company coverage:  SANN.S 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))